Cemiplimab and Fianlimab

WITHDRAWN · PHASE2 · Bladder Urothelial Carcinoma

The sponsor is no longer supporting the trial because they are no longer interested in studying the drug in the target patient population.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.